• Explore /
  • Poster
  • / Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.

Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.

Abstract Poster

Authors

null

Miguel Angel Climent Duran

Instituto Valenciano de Oncología, Valencia, Spain

Miguel Angel Climent Duran , M Isabel Sáez , Josep M. Piulats , A. Montesa , Isabel Chirivella , Alejandro gonzalez Forastero , Cristina Caballero Diaz , Lucia Heras , Begona Mellado , Sergio Vazquez-Estevez , David Olmos , Ignacio Duran , María José Juan Fita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 198)

DOI

10.1200/JCO.2019.37.7_suppl.198

Abstract #

198

Poster Bd #

H19

Abstract Disclosures

Similar Posters

First Author: Constance Thibault

First Author: Antoine Angelergues

Poster

2024 ASCO Genitourinary Cancers Symposium

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.

First Author: Bobby Chi-Hung Liaw

First Author: Alexandra Sokolova